Insulin-like growth factor-I treatment in two children with growth hormone gene deletions

Journal of Pediatric Endocrinology and Metabolism

Volumn 12, Issue 4, 1999, Pages 499-506

  Arnhold, Ivo J P ^a   Oliveira, Suely B ^a   Osorio, Maria G F ^a   Mendonca, Berenice B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Gene; Growth hormone; IGF I treatment; Insulin like growth factor I; Lipohypertrophy

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE ANTIBODY; IGEF; RECOMBINANT GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C; UNCLASSIFIED DRUG;

ARTICLE; CASE REPORT; CATCH UP GROWTH; CHILD; FEMALE; GENE DELETION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HORMONAL THERAPY; HUMAN; LIPOHYPERTROPHY; MALE; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032781816     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.1999.12.4.499     Document Type: Article

References (24)

1. Illig R, Prader A, Ferrandez A, Zachmann M. Hereditary prenatal growth hormone deficiency with increased tendency to growth hormone antibody formation ("A-type" isolated growth hormone deficiency). Acta Paediatr Scand 1971; 60 (Suppl): 607.
2. Phillips JA III, Hjelle BJ, Seeburg PH, Zachmann M. Molecular basis for familial isolated growth hormone deficiency. Proc Natl Acad Sci USA 1981; 78: 6372-6375.
3. Kamijo T, Phillips JA III. Detection of molecular heterogeneity in GH-1 gene deletions by analysis of polymerase chain reaction amplification products. J Clin Endocrinol Metab 1992; 74: 786-789.
4. Rivarola MA, Phillips JA III, Migeon J, Heinrich JJ, Hjelle BJ. Phenotypic heterogeneity in familial isolated growth hormone deficiency type I-A. J Clin Endocrinol Metab 1984; 59: 34-40.
5. Hauffa BP, Illig R, Torresani T, Stolecke H, Phillips JA III. Discordant immune and growth response to pituitary and biosynthetic growth hormone in siblings with isolated growth hormone deficiency type 1A. Acta Endocrinol (Copenh) 1989; 121: 609-614.
6. Laron Z, Kelijman M, Pertzelan A, Keret R, Shoffaer JM, Parks JS. Human growth hormone gene deletion without antibody formation or growth arrest during treatment: a new disease entity? Isr J Med Sci 1985; 21: 999-1006.
7. Laron Z, Blum W, Chatelain P, Ranke M, Rosenfeld R, Savage M, Underwood L. Classification of growth hormone insensitivity syndrome. J Pediatr 1993; 122: 241.
8. Walker JL, Ginalska-Malinowska M, Romer TE, Pucilowska J, Underwood LE. Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron dwarfism). New Engl J Med 1991; 324: 1483-1488.
9. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet 1992; 339: 1258-1261.
10. Walker JL, Van Wyk JJ, Underwood LE. Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 1992; 121: 641-646.
11. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG. A randomized, placebo-controlled trial of safety and efficacy of recombinant insulin-like growth factor-I in chidren with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995; 80: 1393-1398.
12. Klinger B, Laron Z. Three year treatment of children with LS. J Pediatr Endocrinol Metab 1995; 8: 149-158.
13. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Blum MF, Wilton P. Insulin-like growth factor I improves height in growth hormone insensitivity: Two years' results. Horm Res 1995; 44: 253-264.
14. Backeljauw PF, Underwood LE and GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - A clinical research center study. J Clin Endocrinol Metab 1996; 81: 3312-3317.
15. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, Rosenfeld RG. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: Comparison of two dosage levels and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
16. Arnhold IJP, Osorio MGF, Oliveira SB, Estefan V, Kamijo T, Krishnamani MRS, Cogan JD, Phillips III JA, Mendonca BB. Clinical and molecular characterization of Brazilian patients with growth hormone gene deletions. Braz J Med Biol Res 1998; 31: 491-497.
17. Marques RM, Marcondes E, Berquo E, Prandi R, Yunes J. Crescimento e desenvolvimento pubertario em criancas e adolescentes brasileiros: II-Altura e Peso. Sao Paulo: Editora Brasileira de Ciencias; 1982; pp. 97-118.
18. Batista MC, Arnhold IJP, Mendonca BB, D'Abronzo FH, Bloise W, Nicolau W. Low-dose oral clonidine: Effective growth hormone releasing agent in children but not in adolescents. J Pediatr 1987; 111: 564-567.
19. Takano K, Shizume K. Clinical experience with Somatrem in Japan. Acta Paediatr Scand 1986; Suppl 325: 19-24.
20. Klinger B, Garty M, Silbergeld A, Laron Z. Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs. Dev Pharmacol Ther 1990; 15: 196-199.
21. Thorén MC, Wivall-Helleryd IL, Blum WF, Hall KE. Effects of repeated subcutaneous administration of receombinant human insulin-like growth factor I in adults with growth hormone deficiency. Eur J Endocrinol 1994; 131: 33-40.
22. Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Gargosky S, Cohen P, Wilson K, Rosenfeld RG. Hormonal and metabolic effects and pharmacokinetics of human recombinant insulin-like growth factor-I in growth hormone receptor deficiency/LS. J Clin Endocrinol Metabol 1993; 77: 273-280.
23. Clemmons DR, Thissen JP, Maes M, Ketelslegers JM, Underwood LE. Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or protein-deprived rats induces specific IGF-I binding proteins in serum. Endocrinology 1989; 125: 2967-2972.
24. Kanety H, Karasik A, Klinger B, Silbergeld A, Laron Z. Long-term treatment of Laron type dwarfs with insulin-like growth factor-I increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity. Acta Endocrinol (Copenh) 1993; 128: 144-149.